. 2021 Dec 4;15(1):101281. doi: 10.1016/j.tranon.2021.101281

Table 6.

Other receptor antagonists.

Subtype	Drug	Material basis	Model	Effect	Mechanism	References
5-HT antagonists	SB269970	17	MCF-7 T47D MDA-MB-231	Antiproliferation and anti-invasion	Gα-activated cAMP and Gβγ-activated kinase signaling during invasion and Gβγ-activated PI3K/Akt signaling during proliferation	[50]
5-HT antagonists	BJ-1113	19	MCF-7 MDA-MB-231	The inhibitory effect of BJ-1113 against MDA-MB-231 tumor growth was greater than that of SB269970, a 5-HT7 receptor antagonist		[50]
mAChR antagonists	Cevimeline	20	MCF-7 MDA-MB-231	Inhibited cell proliferation	PLC activation	[30]
	4-DAMP	18	MCF-7 MDA-MB-231	Inhibited cell proliferation	PLC activation	[69,120,123]
	Darifenacin	22	MCF-7 MDA-MB-231	Inhibited cell proliferation	PLC activation	[86,99,106]
nAChR antagonists	Epigallocatechin-3-gallate (EGCG)	24	MCF-7	Inhibited cell proliferation	Blocking α9-nAChR signaling pathway	[144]
nAChR antagonists	Garcinol	21	MCF-10A MDA-MB-231 NOD.CB17-PRKDC (SCID)	Inhibited cell proliferation	Downregulate the expression of α9-nAChR and cyclin D3 protein	[27]
mGluR1-specific antagonists	Riluzole	29		Inhibited cell proliferation in a dose-response manner in all EC types	Inhibition of angiogenesis	[41,136]
	BAY36–7620	27			Inhibition of angiogenesis	[25,137]
	YM 298,198	28	MCF-7	Inhibited cell proliferation in all the cell types, except HUVEC	Inhibition of angiogenesis	[135]
H3R antagonists	OUP-186	30	MDA-MB-231 MCF-7	Induced breast cancer cell death	Activated caspase-3/7	[142]
	Clobenpropit	31	MDA-MB-231 MCF-7	Cell death was only slightly induced	Activated caspase-3/7
	JNJ7777120	32	MDA-MB-231 MCF-7	Inhibited cell migration and invasion	Reduced E-cadherin, cytoplasmic and nuclear β-catenin, and nuclear Slug and an increase in vimentin and α-smooth muscle actin expression	[48]
Peptide neurotransmitter antagonists	Scorpion venom	33	MDA-MB-231	Reduced motility and invasion in breast cancer cells	Inhibited MMP activity; upregulation of p53 and downregulation of Bcl-xL and BID protein expression by modulating signaling proteins Erk1/2 and STAT3 and DNA damage in breast and colorectal cancer cell lines	[4,5]
NTS agonist	JMV449	34	MCF-7	Promoted apoptosis	MAPK activation caused the expression of B-cell lymphoma-2 (BCL-2)	[131]
NTS antagonist	SR48692	35				[77]

In summary, we highlight in the Fig. 5 which are the potential targets for drug development.